NeoGraph Analytics
Medical DevicesGlobal2026 – 2032

Surgical Navigation Market Size, Share & Forecast 2026-2032

Surgical navigation market at $1.50B in 2026, reaching $2.19B by 2032 at 6.5% — and why published estimates for the same year differ by a factor of ten.

Revenue, 2026

$1.5B

Forecast, 2032

$2.2B

CAGR, 2026-2032

6.5%

Report Coverage

Global

Code: surgical-navigation-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Surgical navigation carries the widest published spread in this corpus: $1.382 billion to $13.8 billion for the same year, a factor of 9.99. The spread is not uncertainty, it is two different industries sold under one name. The published estimates cluster cleanly at 6.5-6.9% and at 14-15.2%, and the dividing line is surgical robotics. iData alone publishes both halves and labels them — navigation at just under $1.8 billion growing 6.8%, robotics separately at 15.7% — which accounts for the entire gap. We publish the navigation-only reading, Global Market Insights' September 2026 series: $1.50 billion in 2026 to $2.19 billion by 2032 at 6.5%, taken from its own published 2026 base and its own rate, reconciling to 6.51%. The larger cluster does not survive contact with the companies it names. A $13.8 billion navigation market would be 88.5% of Stryker's entire MedSurg and Neurotechnology segment, $15.6 billion in FY2025, which also contains endoscopy, instruments, hospital beds and neurovascular; and 1.40 times Medtronic's entire $9.846 billion Neuroscience portfolio, where navigation appears in the fiscal 2025 release as the phrase 'strength in Navigation capital' and nowhere else. Of the five companies this market rests on, exactly one discloses a line that is mostly navigation capital: Globus Medical's Enabling Technologies, $141.0 million in FY2025 — 10.2% of the smaller published market, 1.02% of the larger. And it fell about 8% on the year, with a record $55.6 million fourth quarter implying the first three averaged $28.5 million. The FDA register agrees with the smaller reading: 16 clearances under product code HAW across 2024 and 2025 combined. Navigation is not a product with its own margin; it is capital placed to secure implant volume, and nobody prices it separately or reports it separately.

02

Key Highlights

1

Headline

$1.50 billion in 2026 to $2.19 billion in 2032 at 6.5%, from Global Market Insights' own published 2026 base and stated rate (implied 6.51%)

2

Published 2025 estimates span 9.99x ($1.382B-$13.8B) — the widest spread in this corpus, and a robotics-inclusion decision rather than a disagreement about growth

3

Globus Medical's Enabling Technologies, the only disclosed navigation-and-robotics capital line in the industry, was $141.0 million in FY2025 — and fell roughly 8%

4

That $141.0 million is 10.2% of the navigation-only market reading and 1.02% of the robotics-inclusive one, which is how the spread gets adjudicated

5

A $13.8 billion navigation market would be 88.5% of Stryker's entire $15.6 billion MedSurg and Neurotechnology segment and 1.40x Medtronic's entire $9.846 billion Neuroscience portfolio

6

16 FDA 510(k) clearances under product code HAW across 2024-2025 combined, against 425 cumulative — the footprint of a concentrated category, not a 15% grower

7

Navigation is mentioned once in Medtronic's whole fiscal 2025 fourth-quarter release, as strength in Navigation capital inside ENT; it is sold to pull through implants, not for its own margin

03

Market Overview

Market Context

Surgical navigation is a mature capital category that the research industry keeps describing as an emerging one, and the mechanism is simple: three publishers put surgical robotics inside it. Strip robotics out and what remains is a tracking camera or field generator, instrumented tools, a workstation and planning software — a product that has been routine in cranial and spine surgery for two decades and whose growth is a mid-single-digit refresh cycle. Four publishers that size it separately all land between 6.5% and 6.92%. Put robotics in and you have an industry with different unit economics, a different buying committee and double the growth rate, and three publishers sell that under the navigation name. The commercial structure explains the disclosure problem. Navigation is not bought for itself; it is placed to secure implant volume, which is why Medtronic attributes its Cranial & Spinal Technologies growth to the AiBLE spine ecosystem and to capital sales driving implant pull-through rather than to navigation revenue, and why there is no separate United States reimbursement code for a navigated procedure. The companies that hold the revenue — Medtronic, Stryker, Zimmer Biomet — report navigation nowhere, because for them it is a sales instrument inside segments of $9.8 billion and $15.6 billion. The one company that is mostly navigation, Brainlab, postponed its Frankfurt IPO two days before trading was due to begin. That leaves Globus Medical's $141 million Enabling Technologies line as the entire public evidence base for a market that three publishers price at over ten billion dollars.

Published surgical navigation estimates for 2025 run from $1.382 billion to $13.8 billion — a 9.99x spread, the widest in this corpus. It is not noise. The estimates fall into two clean clusters at 6.5-6.9% and 14-15.2%, and the dividing line is whether surgical robotics is counted inside the market. iData publishes both sides explicitly: navigation at just under $1.8 billion growing 6.8%, and robotics separately at 15.7%. We publish the navigation-only reading, Global Market Insights' September 2026 series: $1.50 billion in 2026 rising to $2.19 billion by 2032 at 6.5%. The robotics-inclusive figures do not survive contact with the companies they name. A $13.8 billion navigation market would be 88.5% of the whole of Stryker's MedSurg and Neurotechnology segment — a business that also sells endoscopes, power tools, hospital beds and neurovascular coils — and 1.40 times Medtronic's entire $9.846 billion Neuroscience portfolio, in which navigation appears in the FY2025 release as a single phrase, 'strength in Navigation capital'. Of the five companies this sector rests on, exactly one discloses a navigation-and-robotics capital line: Globus Medical's Enabling Technologies, at $141.0 million in FY2025 — and it fell about 8%.

Market Stage

Mature

Adoption Level

Routine in cranial and spine surgery, selective elsewhere

Key Trends

Navigation is being sold as a razor for implants rather than as capital in its own right: Medtronic attributes Cranial & Spinal Technologies growth to adoption of its AiBLE spine surgery ecosystem and cites capital sales driving implant pull-through, not navigation revenueThe one disclosed navigation-and-robotics capital line in the industry shrank: Globus Medical's Enabling Technologies fell roughly 8% to $141.0 million in FY2025, even though its Q4 was a record $55.6 million, against published market CAGRs of 6.5% to 15.2%Capital placements are lumpy and deal-driven: Globus described Enabling Technologies as weak in the first and third quarters of 2025 before elongated pipeline deals closed in the fourth, which is how a $141 million line produces a $55.6 million quarterDisclosure is moving the wrong way. Brainlab, the one large navigation pure-play, postponed its Frankfurt IPO on 1 July 2025 two days before trading was due to start, so the sector's only potential source of standalone navigation financials did not arriveMixed reality is the current platform iteration rather than a new market: Brainlab received FDA 510(k) clearance and launched Spine Mixed Reality Navigation in the United States in September 2025The regulatory footprint is that of a concentrated, mature category: 16 FDA 510(k) clearances under product code HAW, the principal cranial stereotaxic instrument code, across 2024 and 2025 combined, against 425 cumulative clearances since the code existed
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 6.5%

Base Year (2026)

$1.5B

Forecast (2032)

$2.2B

CAGR (2026-2032)

6.5%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$1.50B
2027$1.60B
2028$1.70B
2029$1.81B
2030$1.93B
2031$2.06B
2032$2.19B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at Global Market Insights' stated 6.5% CAGR from its own published 2026 base. How these figures are produced.
Forecast Analysis

Our 6.5% is Global Market Insights' own rate applied to its own 2026 base, and it is corroborated by three other publishers that size navigation apart from robotics — iData at 6.8%, Technavio at 6.92%, QYResearch at 6.5%. That convergence matters more than the level does, because it is four independent houses agreeing once they have made the same scope decision, which is the opposite of the 10x disagreement that appears when they have not. What the rate does not capture is the shape. The only disclosed capital line in the sector, Globus Medical's Enabling Technologies, fell about 8% in FY2025 while booking a record fourth quarter of $55.6 million — meaning the first three quarters averaged $28.5 million and the company's own explanation was elongated pipeline deals finally closing. Navigation capital is a few hundred placements a year decided by hospital capital committees, and it does not compound; it arrives in bursts and then pauses. The structural question underneath the forecast is whether navigation remains a separately purchased capital item at all, or whether it is absorbed entirely into implant contracts as a placed asset, in which case the reported market shrinks while the installed base grows. The directional bets inside the 6.5% that are checkable are ambulatory surgical centres at 7.01% a year on Global Market Insights' own projection, orthopaedic and dental applications at 7.41% and 7.09% against a mature neurology core, and Asia Pacific at 7.93%. Readers should treat any figure above about $2.5 billion for 2026 as including robotics and reprice accordingly.

05

Market Dynamics

  • Implant pull-through, which is the real commercial case: Medtronic's FY2025 release ties Cranial & Spinal Technologies growth to the AiBLE ecosystem and to capital sales driving implant volume, so navigation is bought to secure an implant stream rather than for its own margin
  • Spine and cranial procedure volumes, where navigation has moved from differentiator to expectation and where Globus, Medtronic and Brainlab all compete on the same accounts
  • Ambulatory migration: Global Market Insights projects ambulatory surgical centres as the faster-growing end-use channel at 7.01% a year, reaching $905.49 million by 2035, as cases move out of inpatient hospitals
  • Platform refresh cycles rather than new placements, with mixed reality the current iteration — Brainlab cleared and launched Spine Mixed Reality Navigation in the United States in September 2025
  • Orthopaedic and dental applications growing faster than the core neurology base on Global Market Insights' figures, at 7.41% and 7.09% respectively against 36.6% of the 2024 market sitting in neurology on Grand View's count
06

Market Segmentation

By Type

  • Optical tracking systems
  • Electromagnetic tracking systems
  • Hybrid tracking systems
  • Intraoperative imaging-based navigation
  • Planning and navigation software
  • Service and support

By End User

  • Hospitals and academic medical centres
  • Ambulatory surgical centres
  • Specialty orthopaedic and spine clinics
  • Academic and research institutes

By Application

  • Neurosurgery and cranial
  • Spine surgery
  • Orthopaedics
  • ENT
  • Dental and maxillofacial
07

Competitive Landscape

M

Medtronic plc

Galway, Ireland (operational headquarters: Minneapolis, Minnesota, United States)

The broadest navigation franchise — StealthStation cranial and spinal navigation, O-arm imaging and Mazor robotics — and the clearest illustration of why this market cannot be benchmarked. Navigation appears in Medtronic's entire FY2025 fourth-quarter release as a single phrase, 'strength in Navigation capital', inside a comment on low-single-digit ENT growth. No navigation revenue is disclosed and we assign no share.

FY2025 Neuroscience portfolio revenue $9.846 billion, up 4.7% reported and 5.2% organic, comprising Cranial & Spinal Technologies, Specialty Therapies and Neuromodulation. Cranial & Spinal Technologies grew 5% for the year, attributed to adoption of the AiBLE spine surgery ecosystem, with fourth-quarter revenue of $1,266 million against $1,244 million. Fourth-quarter results were described as driven by strong United States capital sales and implant pull-through — the commercial logic of navigation in one sentence.

S

Stryker Corporation

Portage, Michigan, United States

Holds the largest robotics franchise in orthopaedics through Mako, alongside cranial and ENT navigation, and reports all of it inside a segment so broad that it sets the ceiling for this whole analysis: a $13.8 billion global navigation market would be 88.5% of it. No navigation or Mako revenue is disclosed and no share is assigned.

FY2025 consolidated net sales $25.1 billion, up 11.2% reported and 10.7% in constant currency. MedSurg and Neurotechnology — which contains Mako robotics and navigation alongside endoscopy, instruments, medical equipment, neurovascular, CMF and ENT — was $15.6 billion, up 15.7% reported and 15.4% in constant currency, of which about 4.7 points came from acquisitions and divestitures and 10.7% was organic. Orthopaedics was about $9.5 billion, up 4.3%.

G

Globus Medical, Inc.

Audubon, Pennsylvania, United States

The only company in this market that publishes a revenue line which is mostly navigation and robotics capital, and therefore the single hardest number available: Enabling Technologies at $141.0 million in FY2025, down roughly 8%. That is about 10% of the navigation-only market reading and about 1% of the robotics-inclusive one — which is how the 10x spread gets adjudicated. Share is not disclosed and we assign none.

FY2025 net sales $2,938.9 million, up 16.7% reported, of which Musculoskeletal Solutions was $2,797.9 million and Enabling Technologies — the ExcelsiusGPS navigation and robotics platform — was $141.0 million, or 4.8% of the company. Enabling Technologies was lumpy through the year, weak in the first and third quarters before a record fourth quarter of $55.6 million as elongated pipeline deals closed. Nevro contributed $293.6 million for the year; the base business excluding Nevro grew 5.0%.

B

Brainlab SE

Munich, Germany

The largest independent navigation specialist and the only player whose business is mostly navigation rather than implants — which is exactly why its financials are not public. It postponed its Frankfurt Prime Standard IPO on 1 July 2025, two days before trading was due to begin. No audited full-year revenue figure exists in public, and third-party trackers disagree by more than 40%, so we name and characterise it without sizing it.

Cranial, spine and ENT navigation, image-guided planning software and the Loop-X mobile imaging platform. Its June 2025 IPO announcement cited record revenue of EUR 239 million for the first half of FY2024/25 reflecting portfolio adjustments, a 22.4% EBITDA margin, a primary capital increase of up to EUR 200 million, and mid-term targets of 10-13% revenue growth at a mid-20s EBITDA margin. Received FDA 510(k) clearance and launched Spine Mixed Reality Navigation in the United States in September 2025.

Z

Zimmer Biomet Holdings, Inc.

Warsaw, Indiana, United States

Competes in orthopaedic navigation and robotics through ROSA, sold as an enabling platform for its knee and hip implant portfolio. ROSA revenue is not separately disclosed in Zimmer Biomet's segment reporting, so its position is characterised from product strategy only and no share is assigned.

ROSA Knee, Hip and Brain robotic and navigation platforms, positioned to pull through Persona and other implant systems. The company reports by geography and by product category rather than by enabling technology, so no navigation or robotics revenue line is published.

N

Northern Digital Inc. (NDI)

Waterloo, Ontario, Canada

The component supplier most navigation systems depend on without the hospital ever seeing the name. Its Polaris optical trackers are cited by one publisher as an example of the market's technology, and several vendors' systems are built around them. Privately held; no revenue is disclosed.

Optical and electromagnetic measurement and tracking systems supplied to medical device manufacturers as the position-sensing layer inside branded surgical navigation platforms. Privately held and reports no financial figures.

08

Recent Developments

26
2026Globus Medical, Inc.

Reported FY2025 results on 25 February 2026: net sales of $2,938.9 million, up 16.7%, with Enabling Technologies — the ExcelsiusGPS navigation and robotics platform and the only disclosed navigation capital line in the industry — at $141.0 million, down roughly 8% for the year despite a record fourth quarter of $55.6 million.

26
2026Stryker Corporation

Reported FY2025 results on 29 January 2026: consolidated net sales of $25.1 billion, up 11.2%, with MedSurg and Neurotechnology — the segment containing Mako robotics and surgical navigation alongside endoscopy, instruments and medical equipment — at $15.6 billion, up 15.7% reported with 10.7% organic growth and no navigation split.

25
2025Brainlab SE

Postponed its planned initial public offering and Prime Standard listing on the Frankfurt Stock Exchange on 1 July 2025, two days before trading was due to begin on 3 July, saying an IPO at a later time remains under consideration — leaving the surgical navigation sector with no pure-play public filer.

25
2025Brainlab SE

Received FDA 510(k) clearance and launched Spine Mixed Reality Navigation in the United States in September 2025, the current platform iteration in a category where growth comes from refresh cycles on an installed base rather than from new placements.

25
2025Medtronic plc

Reported fiscal 2025 Neuroscience portfolio revenue of $9.846 billion on 21 May 2025, up 4.7% reported and 5.2% organic, with Cranial & Spinal Technologies up 5% on adoption of the AiBLE spine surgery ecosystem and fourth-quarter growth attributed to strong United States capital sales and implant pull-through. Navigation is mentioned once in the release, as strength in Navigation capital inside ENT.

09

Regulatory Landscape

Surgical navigation systems reach the United States market through the FDA 510(k) premarket notification pathway. The principal cranial code is HAW, neurological stereotaxic instrument, under regulation 21 CFR 882.4560; the openFDA database records 425 cumulative clearances under that code and 16 with decision dates in 2024 and 2025 combined, a footprint consistent with a concentrated category iterating on established platforms.Navigation software is regulated as a device in its own right. Planning, segmentation and registration software carries its own clearance obligations, and FDA's guidance on clinical decision support and on software as a medical device governs how much autonomy a navigation algorithm may exercise over instrument placement.EU Medical Device Regulation 2017/745 governs any navigation platform placed on the EU market, with notified-body conformity assessment, unique device identification and post-market clinical follow-up obligations, and with a higher classification where the software directs an active surgical instrument.Navigation platforms that incorporate intraoperative imaging — cone-beam CT, fluoroscopy or mobile imaging such as Brainlab's Loop-X — additionally fall under radiation-emitting electronic product performance standards at 21 CFR part 1020 in the United States and equivalent national radiological protection licensing elsewhere.There is no separate reimbursement code for navigation in the United States. Navigated procedures are billed under the same CPT codes as their open or fluoroscopy-guided equivalents, with stereotactic guidance add-on codes available in limited circumstances, which is why navigation is commercially a means of securing implant volume rather than a revenue line of its own.No regulator or registry publishes counts of navigated procedures. CMS and the American Hospital Association publish surgical volumes, but the navigated share of them is not collected anywhere public, so attach rates cannot be computed from official statistics.
10

Research Methodology

Secondary research

  • Global Market Insights, Surgical Navigation Systems Market, report GMI5908, published September 2026 — $1.382B (2025), $1.5B (2026), $2,571.48M (2035), 6.5% (2026-2035), with technology, application, end-use and regional segment values
  • SkyQuest Technology, Surgical Navigation Systems Market, published December 2025 — $11.98B (2024), $13.8B (2025), $42.81B (2033), 15.2% (2026-2033)
  • Grand View Research, surgical navigation systems market press release, October 2024 — $18.47B by 2030 at 14.0% (2025-2030); electromagnetic 40.7% and neurology 36.6% of 2024; Horizon application-level 2024 value $8,377.9M
  • Globus Medical, Inc., fourth quarter and full year 2025 results, 25 February 2026 — net sales $2,938.9M, Enabling Technologies $141.0M full year and $55.6M in Q4, Nevro $293.6M
  • Stryker Corporation, 2025 operating results, 29 January 2026, and Form 10-K for FY2025 (SEC EDGAR, CIK 310764) — MedSurg and Neurotechnology $15.6B, consolidated $25.1B
  • Medtronic plc, fourth quarter and fiscal year 2025 results, 21 May 2025, and Form 10-K for fiscal 2025 (SEC EDGAR, CIK 1613103) — Neuroscience $9.846B, Q4 Cranial & Spinal Technologies $1,266M
  • U.S. FDA 510(k) premarket notification database via the openFDA API, queried 16 October 2026 (endpoint last updated 5 October 2026) — product code HAW, regulation 21 CFR 882.4560: 425 cumulative clearances, 16 with decision dates in 2024-2025
  • Brainlab SE, ad-hoc announcement postponing its planned IPO, 1 July 2025, and its June 2025 offering announcement citing EUR 239 million of first-half FY2024/25 revenue
  • iData Research, surgical navigation market at just under $1.8 billion growing 6.8%, published separately from surgical robotics at 15.7%
  • QYResearch, surgical navigation projection system market — $1,346M (2025) to $1,964M (2031) at 6.5%; and Technavio, surgical navigation systems at 6.92% (2023-2028)

Validation: The 2026 base is Global Market Insights' own published 2026 figure of $1.5 billion, unaltered; the 2032 endpoint is derived by compounding it at GMI's own stated 6.5% rate and is labelled as interpolation. The internal check is that the implied rate between our endpoints is 6.51% against GMI's stated 6.5%. GMI was chosen because it is the most recently published estimate in the set with a dated base year, because it publishes the most granular segmentation and is therefore the most checkable, and because 6.5% is independently corroborated by iData, Technavio and QYResearch, all of which land between 6.5% and 6.92% when they size navigation separately from robotics. Three grounding tests were run against audited FY2025 segment revenue and a public regulatory register. First, the one disclosed navigation line: Globus Medical's Enabling Technologies segment — the ExcelsiusGPS navigation and robotics platform — was $141.0 million in FY2025, which is 10.2% of GMI's $1.382 billion 2025 market and 1.02% of SkyQuest's $13.8 billion. Globus is one of roughly five vendors with a commercial cranial or spinal navigation-robotics platform, so a tenth is plausible for the smallest of five and a hundredth would require the other four to generate $13.66 billion of navigation capital between them. Second, a ceiling test from the largest reported containers: SkyQuest's $13.8 billion is 88.5% of Stryker's entire $15.6 billion MedSurg and Neurotechnology segment, a business that also sells endoscopes, instruments, hospital beds and neurovascular products, and 1.40 times Medtronic's entire $9.846 billion Neuroscience portfolio, in which navigation is mentioned once in the FY2025 release as strength in Navigation capital inside ENT. The robotics-inclusive cluster is therefore ruled out. Reconstructing from Globus's line in the other direction brackets the navigation-only reading at roughly $1.3 to $2.5 billion, which is GMI's and iData's cluster. Third, a register check: the openFDA 510(k) database records 425 cumulative clearances under product code HAW, the principal neurological stereotaxic instrument code at 21 CFR 882.4560, and 16 with decision dates in 2024 and 2025 combined — eight a year, the footprint of a concentrated category rather than of a $13.8 billion market growing at 15.2%. These are scope and plausibility tests, not market estimates. Globus's Enabling Technologies segment contains robotics as well as navigation, so using it as a navigation proxy overstates navigation; the Stryker and Medtronic figures are ceilings rather than estimates; 510(k) counts are a regulatory artefact that does not scale with revenue, and HAW misses orthopaedic and ENT navigation cleared under other codes. Regional and country splits are published as empty arrays because the only source offering them splits a 2022 base it does not reconcile against its own technology table for the same year, and segmentation is published as plain strings for the same reason. No vendor market share is published because none of Medtronic, Stryker, Brainlab, Zimmer Biomet or Globus discloses navigation revenue.

11

Strategic Takeaways

Establish whether a surgical navigation figure includes robotics before you use it. The two clusters are 6.5-6.9% and 14-15.2%, and the gap at 2025 is $1.382 billion against $13.8 billion. iData publishes both halves separately and labels them.

The large estimates can be falsified from public filings. $13.8 billion is 88.5% of Stryker's entire MedSurg and Neurotechnology segment and 1.40 times Medtronic's entire Neuroscience portfolio, inside both of which navigation is a capital adjunct.

Globus Medical's $141.0 million Enabling Technologies line is the only disclosed navigation capital revenue in the industry. Anchor on it

a tenth of a $1.4 billion market is plausible, a hundredth of a $13.8 billion one is not.

Do not expect smooth growth. The one visible line fell about 8% in FY2025 while posting a record quarter, because navigation capital is a few hundred hospital-committee decisions a year, not a demand curve.

Understand why the number is hidden. Navigation is placed to pull through implants and has no separate reimbursement code, so no vendor prices it separately — and the one pure-play, Brainlab, postponed its IPO two days before trading.

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.